title: Antitumor effects of interleukin 2 against renal cell carcinoma: basic study and clinical application.
abstract: In order to determine an optimum mode for systemic administration of recombinant interleukin 2 (rIL2), the effects of rIL2 on lymphocyte-mediated cytotoxicity against renal carcinoma cells were studied in vitro. Augmentation of the cytotoxicity by rIL2 was dose- and time-dependent. The optimum dose of rIL2 was 100-500 units (Jurkat units)/ml, and cytotoxicity increased significantly even at a low concentration such as 4 units/ml. We thus chose daily administration of multiple repeated dose for inpatients. To prevent withdrawal from the therapy as a result of untolerable adverse effects, the daily dose was set at 1 X 10(6) units, and rIL2 was given to 12 patients with metastatic renal cell carcinoma. Two-hour intravenous drip infusions containing 5 X 10(5) units of rIL2 was given daily 2 times to inpatients and after at least 28 days of this mode of administration, subcutaneous injection at a dose of 1 X 10(6) units was given 6 days a week to outpatients. Three patients showed complete response, 7 patients no change, and 2 patients progressive disease. Serious adverse effects due to capillary leak syndrome were not observed. We conclude that low-dose rIL2 is safe and has potential antitumor effects.
authors.affiliation: Department of Urology, School of Medicine, Keio University, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Marumo
authors.forename: M
authors.initials: M
authors.lastname: Ueno
authors.forename: J
authors.initials: J
authors.lastname: Muraki
authors.forename: M
authors.initials: M
authors.lastname: Tachibana
authors.forename: N
authors.initials: N
authors.lastname: Deguchi
authors.forename: S
authors.initials: S
authors.lastname: Baba
authors.forename: S
authors.initials: S
authors.lastname: Jitsukawa
authors.forename: M
authors.initials: M
authors.lastname: Hata
authors.forename: H
authors.initials: H
authors.lastname: Tazaki
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins